Mantra Bio, a San Francisco, CA-based developer of targeted therapeutics based on its engineering platform, raised $9M in Series A-2M funding.
New investor, Samsung Securities, joined existing investors, including 8VC, Viking Global Investors, Illumina, BoxGroup and Allen & Company in the round.
The company intends to use the funds to advance the development of its lead targeted exosome therapeutics program.
Led by Alex Mok, CEO, Mantra Bio is developing targeted therapeutics based on its proprietary exosome engineering platform, REVEAL. The platform, which integrates computational biology and bench lab automation, leverages the diversity of exosomes to enable the rational design of therapeutics directed at a wide range of tissue and cellular targets. The company’s programs include targeted exosome therapeutics for the treatment of certain ocular diseases and a novel vaccine for infectious disease. The lead program, in ophthalmology, employs engineered bi-specific exosomes that precisely target multiple disease pathways.
Mantra’s overall Series A funding, including a $25M Series A-1, totals $34M.
FinSMEs
05/01/2023